MA31108B1 - Derives substitues de spirochromanone en tant qu'inhibiteurs d'acc - Google Patents
Derives substitues de spirochromanone en tant qu'inhibiteurs d'accInfo
- Publication number
- MA31108B1 MA31108B1 MA32114A MA32114A MA31108B1 MA 31108 B1 MA31108 B1 MA 31108B1 MA 32114 A MA32114 A MA 32114A MA 32114 A MA32114 A MA 32114A MA 31108 B1 MA31108 B1 MA 31108B1
- Authority
- MA
- Morocco
- Prior art keywords
- group
- cyclo
- alkyl
- alkoxy
- optionally substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pregnancy & Childbirth (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
La présente invention concerne un composé de formule générale (i) : (i) dans laquelle ar1 représente un groupe formé à partir d'un cycle aromatique choisi dans un groupe comprenant un indole, un 1h-indazole, un 2h-indazole, un 1h-thiéno[2,3-c]pyrazole, un 1h-pyrazolo[3,4-b]pyridine, un benzo[b]furanne, un benzimidazole, un benzoxazole, un 1,2-benzisoxazole et un imidazo[1,2-a]pyridine ; r1 et r2 représentent chacun un atome d'hydrogène, un atome d'halogène, un groupe cyano, un groupe alkényle en c2-c6, un groupe alcoxy en c1-c6, un groupe halo-alcoxy en c1-c6, un groupe cyclo-alkyloxy en c3-c6, un groupe alcanoyle en c2-c7, un groupe halo-alcanoyle en c2-c7, un groupe alcoxycarbonyle en c2-c7, un groupe halo-alcoxycarbonyle en c2-c7, un groupe cyclo-alkyloxycarbonyle en c3-c6, un groupe aralkyloxycarbonyle, un groupe carbamoyl-alcoxy en c1-c6, un groupe carboxy-alkényle en c2-c6 ou un groupe de -q1-n(ra)-q2-rb ; un groupe alkyle en c1-c6, aryle ou hétérocyclique facultativement substitué ; ou un groupe alkyle en c1-c6 ou alkényle en c2-c6 ayant le groupe aryle ou hétérocyclique ; r3 et r4 représentent chacun un atome d'hydrogène, un atome d'halogène, un groupe nitro, un groupe cyclo-alkyle en c3-c6, un groupe carbamoyle facultativement substitué avec un groupe alkyle en c1-c6 ou cyclo-alkyle en c3-c6 ou un groupe de -n(re)rf ; un groupe alcanoyle en c2-c7, alcoxy en c1-c6, alcoxycarbonyle en c2-c7, cyclo-alkyloxycarbonyle en c3-c6, alkylsulfonyle en c1-c6, alkylthio en c1-c6, cyclo-alkyloxy en c3-c6, cyclo-alkyle en c3-c6-alcoxy en c1-c6, cyclo-alkylsulfonyle en c3-c6, cyclo-alkylthio en c3-c6 or cyclo-alkyle en c3-c6 alkylthio-c1-c6 facultativement substitué ; ou un groupe alkyle en c1-c6 facultativement substitué ; t et u représentent chacun un atome d'azote ou un groupe méthine ; et v représente un atome d'oxygène ou un atome de soufre. Le composé de l'invention est utilisable en tant qu'agent thérapeutique pour diverses maladies liées à l'acc.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88030207P | 2007-01-12 | 2007-01-12 | |
PCT/US2008/000221 WO2008088688A1 (fr) | 2007-01-12 | 2008-01-08 | Dérivés substitués de spirochromanone en tant qu'inhibiteurs d'acc |
Publications (1)
Publication Number | Publication Date |
---|---|
MA31108B1 true MA31108B1 (fr) | 2010-01-04 |
Family
ID=39297859
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA32114A MA31108B1 (fr) | 2007-01-12 | 2009-07-23 | Derives substitues de spirochromanone en tant qu'inhibiteurs d'acc |
Country Status (28)
Country | Link |
---|---|
US (1) | US8093389B2 (fr) |
EP (1) | EP2111406B1 (fr) |
JP (1) | JP5319550B2 (fr) |
KR (1) | KR20090108022A (fr) |
CN (1) | CN101631791B (fr) |
AR (1) | AR064824A1 (fr) |
AU (1) | AU2008205638B2 (fr) |
BR (1) | BRPI0806531A2 (fr) |
CA (1) | CA2674573C (fr) |
CL (1) | CL2008000067A1 (fr) |
CO (1) | CO6190611A2 (fr) |
CR (1) | CR10944A (fr) |
DO (1) | DOP2009000176A (fr) |
EC (1) | ECSP099503A (fr) |
GT (1) | GT200900194A (fr) |
HK (1) | HK1131136A1 (fr) |
HN (1) | HN2009001276A (fr) |
MA (1) | MA31108B1 (fr) |
MX (1) | MX2009007502A (fr) |
NI (1) | NI200900139A (fr) |
NZ (1) | NZ577825A (fr) |
PE (1) | PE20081559A1 (fr) |
RU (1) | RU2009130736A (fr) |
SG (1) | SG177977A1 (fr) |
TW (1) | TW200836727A (fr) |
UA (1) | UA103990C2 (fr) |
WO (2) | WO2008088689A1 (fr) |
ZA (1) | ZA200904138B (fr) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE509023T1 (de) * | 2005-07-19 | 2011-05-15 | Merck Sharp & Dohme | Spirochromanon-derivate als acetyl-koenzym-a- carboxylase-hemmer |
AU2008205642B2 (en) * | 2007-01-12 | 2013-06-06 | Msd K.K. | Spirochromanon derivatives |
WO2009097995A1 (fr) * | 2008-02-07 | 2009-08-13 | Sanofi-Aventis | Nouvelles imidazolidines substituées par un phényle, procédé de production, médicaments contenant ces composés et leur utilisation |
US8318762B2 (en) * | 2008-05-28 | 2012-11-27 | Pfizer Inc. | Pyrazolospiroketone acetyl-CoA carboxylase inhibitors |
CA2729412A1 (fr) * | 2008-07-04 | 2010-01-07 | Banyu Pharmaceutical Co., Ltd. | Nouveaux acides spirochromanone carboxyliques |
EP2310015A4 (fr) * | 2008-07-14 | 2011-10-26 | Cropsolution Inc | Modulateurs de l acétyl-coenzyme a carboxylase et procédés d utilisation associés |
JP5689069B2 (ja) | 2008-11-20 | 2015-03-25 | ジェネンテック, インコーポレイテッド | ピラゾロピリジンpi3k阻害剤化合物及び使用方法 |
MX2012005429A (es) * | 2009-11-10 | 2012-06-19 | Pfizer | Inhibidores de n1-pirazoloespirocetona acetil-coa carboxilasa. |
EP3085402B1 (fr) * | 2009-12-31 | 2018-05-09 | DEKA Products Limited Partnership | Ensemble de pompe à perfusion |
WO2011140425A1 (fr) | 2010-05-06 | 2011-11-10 | Vertex Pharmaceuticals Incorporated | Amides de chromène hétérocyclique-pipéridine spirocyclique utiles comme modulateurs des canaux ioniques |
CN101851237B (zh) * | 2010-06-18 | 2012-10-17 | 南方医科大学 | 一种螺环化合物及其制备方法和应用 |
WO2011157827A1 (fr) | 2010-06-18 | 2011-12-22 | Sanofi | Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases |
DK2621493T3 (en) | 2010-09-30 | 2016-10-24 | Pfizer | N1 PYRAZOLOSPIROKETON-ACETYL-CoA carboxylase INHIBITORS |
AU2011322117B2 (en) | 2010-10-29 | 2015-01-22 | Pfizer Inc. | N1/N2-lactam acetyl-CoA carboxylase inhibitors |
WO2012077655A1 (fr) * | 2010-12-07 | 2012-06-14 | 塩野義製薬株式会社 | Dérivé spiro présentant une activité agoniste de gpr119 |
PT2670752E (pt) | 2011-02-02 | 2016-06-14 | Vertex Pharma | Piperidinamidas pirrolopirazina-espirocíclicas como moduladores de canais iónicos |
WO2012112743A1 (fr) | 2011-02-18 | 2012-08-23 | Vertex Pharmaceuticals Incorporated | Amides de pipéridine spirocyclique chromanique en tant que modulateurs des canaux ioniques |
MX347982B (es) | 2011-03-14 | 2017-05-22 | Vertex Pharma | Morfolina-piperidina espirociclica-amidas como moduladores de canales ionicos. |
CU24164B1 (es) | 2011-04-22 | 2016-03-31 | Pfizer | Inhibidores sustituidos de acetil-coa carboxilasa |
TW201300393A (zh) * | 2011-05-20 | 2013-01-01 | Kowa Co | 新穎之螺哌啶衍生物及含有其之醫藥 |
WO2013113773A1 (fr) | 2012-02-03 | 2013-08-08 | Basf Se | Composés fongicides de pyrimidine |
WO2013113776A1 (fr) | 2012-02-03 | 2013-08-08 | Basf Se | Composés de pyrimidine fongicides |
WO2013113791A1 (fr) | 2012-02-03 | 2013-08-08 | Basf Se | Composés de pyrimidine fongicides |
IN2014DN07220A (fr) | 2012-02-03 | 2015-04-24 | Basf Se | |
CA2862346A1 (fr) | 2012-02-03 | 2013-08-08 | Basf Se | Composes de pyrimidine fongicides |
WO2013113720A1 (fr) | 2012-02-03 | 2013-08-08 | Basf Se | Composés de pyrimidine fongicides |
WO2013113716A1 (fr) | 2012-02-03 | 2013-08-08 | Basf Se | Composés de pyrimidine fongicides |
US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
CA2905242C (fr) | 2013-03-15 | 2016-11-29 | Pfizer Inc. | Composes indoliques activant l'ampk |
AU2014262638A1 (en) | 2013-05-10 | 2015-11-26 | Gilead Apollo, Llc | ACC inhibitors and uses thereof |
EP2994141A4 (fr) | 2013-05-10 | 2016-11-23 | Nimbus Apollo Inc | Inhibiteurs de l'acc et utilisations associées |
BR112016004118A2 (pt) | 2013-09-12 | 2017-10-17 | Pfizer | uso de inibidores da acetil-coa carboxilase para tratamento de acne vulgar |
MX2019006920A (es) | 2016-12-14 | 2019-11-28 | 89Bio Ltd | Derivados de la espiropiperidina. |
MX2019015849A (es) * | 2017-06-30 | 2020-08-03 | Quixgen Inc | Nuevos compuestos de espirolactona. |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2814983A1 (de) | 1978-04-07 | 1979-10-18 | Bayer Ag | Neue chromanon-derivate |
US5206240A (en) | 1989-12-08 | 1993-04-27 | Merck & Co., Inc. | Nitrogen-containing spirocycles |
JPH03182725A (ja) | 1989-12-08 | 1991-08-08 | Internatl Business Mach Corp <Ibm> | 非線形光学素子及びその製造方法 |
IL96507A0 (en) | 1989-12-08 | 1991-08-16 | Merck & Co Inc | Nitrogen-containing spirocycles and pharmaceutical compositions containing them |
NZ243065A (en) | 1991-06-13 | 1995-07-26 | Lundbeck & Co As H | Piperidine derivatives and pharmaceutical compositions |
EP0681571B1 (fr) | 1993-01-28 | 1998-07-29 | Merck & Co. Inc. | Azacycles spiro-substitues utilises comme antagonistes de recepteur de tachykinine |
US5856083A (en) | 1994-05-06 | 1999-01-05 | Pharmacopeia, Inc. | Lawn assay for compounds that affect enzyme activity or bind to target molecules |
US6017768A (en) | 1994-05-06 | 2000-01-25 | Pharmacopeia, Inc. | Combinatorial dihydrobenzopyran library |
US5688997A (en) | 1994-05-06 | 1997-11-18 | Pharmacopeia, Inc. | Process for preparing intermediates for a combinatorial dihydrobenzopyran library |
CA2189634A1 (fr) | 1994-05-06 | 1995-11-16 | John J. Baldwin | Bibliotheque combinatoire de dihydrobenzopyranes |
AU705661B2 (en) | 1995-06-06 | 1999-05-27 | Merck & Co., Inc. | Alpha 1a adrenergic receptor antagonists |
GB9601724D0 (en) | 1996-01-29 | 1996-03-27 | Merck Sharp & Dohme | Therapeutic agents |
GB0003397D0 (en) | 2000-02-14 | 2000-04-05 | Merck Sharp & Dohme | Therapeutic agents |
WO2002020509A2 (fr) | 2000-09-06 | 2002-03-14 | Bayer Aktiengesellschaft | Medicament pour lutter contre des maladies virales |
JP2005162612A (ja) | 2002-01-09 | 2005-06-23 | Ajinomoto Co Inc | アシルスルホンアミド誘導体 |
JP2005170790A (ja) | 2002-01-09 | 2005-06-30 | Ajinomoto Co Inc | N−アルキルスルフォニル置換アミド誘導体 |
EP1478437B1 (fr) | 2002-02-27 | 2005-08-31 | Pfizer Products Inc. | Inhibiteurs de l'acetyl-coa-carboxylase |
JP2005320250A (ja) | 2002-05-09 | 2005-11-17 | Ajinomoto Co Inc | ビスラクトン誘導体及びその医薬組成物としての使用 |
AU2003299791A1 (en) | 2002-12-20 | 2004-07-22 | Bayer Pharmaceuticals Corporation | Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity |
WO2004092179A1 (fr) | 2003-04-14 | 2004-10-28 | Nippon Soda Co. Ltd. | Derive spiro, procede de production et antioxydant |
FR2856685B1 (fr) | 2003-06-25 | 2005-09-23 | Merck Sante Sas | Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent |
JP2005119987A (ja) * | 2003-10-15 | 2005-05-12 | Ajinomoto Co Inc | アシルスルホンアミド誘導体 |
US8138342B2 (en) * | 2004-10-12 | 2012-03-20 | High Point Pharmacueticals, LLC | 11β-hydroxysteroid dehydrogenase type 1 active spiro compounds |
CN101103016A (zh) | 2004-11-18 | 2008-01-09 | 因塞特公司 | 11-β羟基类固醇脱氢酶1型抑制剂及其使用方法 |
EP1879863A1 (fr) * | 2005-05-03 | 2008-01-23 | Pfizer, Inc. | Composes d'amide resorcinol |
ATE509023T1 (de) * | 2005-07-19 | 2011-05-15 | Merck Sharp & Dohme | Spirochromanon-derivate als acetyl-koenzym-a- carboxylase-hemmer |
EP2097420B1 (fr) | 2006-11-29 | 2012-04-04 | Pfizer Products Inc. | Spirocétone inhibiteurs de la acétyl-coa carboxylase |
AU2008205642B2 (en) * | 2007-01-12 | 2013-06-06 | Msd K.K. | Spirochromanon derivatives |
-
2008
- 2008-01-04 PE PE2008000089A patent/PE20081559A1/es not_active Application Discontinuation
- 2008-01-07 TW TW097100608A patent/TW200836727A/zh unknown
- 2008-01-08 AU AU2008205638A patent/AU2008205638B2/en not_active Ceased
- 2008-01-08 US US12/007,000 patent/US8093389B2/en active Active
- 2008-01-08 BR BRPI0806531-4A2A patent/BRPI0806531A2/pt not_active IP Right Cessation
- 2008-01-08 WO PCT/US2008/000223 patent/WO2008088689A1/fr active Application Filing
- 2008-01-08 SG SG2012002739A patent/SG177977A1/en unknown
- 2008-01-08 CN CN2008800021443A patent/CN101631791B/zh not_active Expired - Fee Related
- 2008-01-08 MX MX2009007502A patent/MX2009007502A/es unknown
- 2008-01-08 EP EP08713050A patent/EP2111406B1/fr active Active
- 2008-01-08 JP JP2009545577A patent/JP5319550B2/ja not_active Expired - Fee Related
- 2008-01-08 KR KR1020097014377A patent/KR20090108022A/ko not_active Application Discontinuation
- 2008-01-08 WO PCT/US2008/000221 patent/WO2008088688A1/fr active Application Filing
- 2008-01-08 UA UAA200908468A patent/UA103990C2/ru unknown
- 2008-01-08 NZ NZ577825A patent/NZ577825A/en not_active IP Right Cessation
- 2008-01-08 RU RU2009130736/04A patent/RU2009130736A/ru not_active Application Discontinuation
- 2008-01-08 CA CA2674573A patent/CA2674573C/fr not_active Expired - Fee Related
- 2008-01-09 AR ARP080100081A patent/AR064824A1/es not_active Application Discontinuation
- 2008-01-10 CL CL200800067A patent/CL2008000067A1/es unknown
-
2009
- 2009-06-12 ZA ZA200904138A patent/ZA200904138B/xx unknown
- 2009-07-06 HN HN2009001276A patent/HN2009001276A/es unknown
- 2009-07-06 GT GT200900194A patent/GT200900194A/es unknown
- 2009-07-08 NI NI200900139A patent/NI200900139A/es unknown
- 2009-07-09 EC EC2009009503A patent/ECSP099503A/es unknown
- 2009-07-09 DO DO2009000176A patent/DOP2009000176A/es unknown
- 2009-07-13 CO CO09072490A patent/CO6190611A2/es active IP Right Grant
- 2009-07-20 CR CR10944A patent/CR10944A/es unknown
- 2009-07-23 MA MA32114A patent/MA31108B1/fr unknown
- 2009-11-13 HK HK09110661.8A patent/HK1131136A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA31108B1 (fr) | Derives substitues de spirochromanone en tant qu'inhibiteurs d'acc | |
MA31109B1 (fr) | Nouveaux derives d'aminopyrimidine servant d'inhibiteurs de la plk1. | |
WO2008088692A3 (fr) | Dérivés spirochromanone | |
Cheong et al. | A patent review of IDO1 inhibitors for cancer | |
Chandna et al. | Synthesis of novel celecoxib analogues by bioisosteric replacement of sulfonamide as potent anti-inflammatory agents and cyclooxygenase inhibitors | |
Harfenist et al. | Selective inhibitors of monoamine oxidase. 3. Structure− activity relationship of tricyclics bearing imidazoline, oxadiazole, or tetrazole groups | |
Grassberger et al. | Preparation and antibacterial activities of new 1, 2, 3-diazaborine derivatives and analogs | |
ES2401679T3 (es) | Derivados de 6-1H-imidazo-quinazolina y de quinolinas, nuevos inhibidores de MAO y ligandos del receptor de imidazolina | |
Fei et al. | New substituted benzimidazole derivatives: a patent review (2010–2012) | |
CA3015271C (fr) | Derives de dioxyde d'iminothiadiazinane utilises comme inhibiteurs de la plasmepsine v | |
Schmidt et al. | New pyrazolium-carboxylates as structural analogues of the pseudo-cross-conjugated betainic alkaloid nigellicine | |
ZA200500022B (en) | 1-(Aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligans | |
JP2006517966A (ja) | 5−ヒドロキシトリプタミン−6リガンドとしてのヘテロサイクリル−3−スルホニルアザインドールまたは−アザインダゾール誘導体 | |
CA2729690A1 (fr) | Nouveaux pyrrolo [2,3-a] carbazoles et leur utilisation comme inhibiteurs des kinases pim | |
Rotella et al. | N-3-substituted imidazoquinazolinones: potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction | |
AU2018326721B2 (en) | Compounds and compositions for IRE1 inhibition | |
Wurz et al. | Discovery of imidazopyridazines as potent Pim-1/2 kinase inhibitors | |
Tiwari et al. | Copper-catalyzed synthesis of benzoxazoles via tandem cyclization of 2-halophenols with amidines | |
Zeng et al. | Discovery of potent dipeptidyl peptidase IV inhibitors through pharmacophore hybridization and hit-to-lead optimization | |
Jiang et al. | Regio-and diastereoselective synthesis of 3, 4-dihydro-2H-benzo [4, 5] imidazo [2, 1-b][1, 3] thiazine derivatives via DBU-catalyzed [3+ 3] annulation of MBH carbonates with 2-mercaptobenzimidazoles | |
AR036735A1 (es) | Derivados de 5-metoxi-8-aril-[1,2,4]triazolo[1,5-a]piridina | |
Badrey et al. | An approach to polysubstituted triazipines, thiadiazoles and thiazoles based on benzopyran moiety through the utility of versatile hydrazonoyl halides as in vitro monoamine oxidase inhibitors | |
CA2935985A1 (fr) | Composes organiques | |
Lotfata et al. | A Simple and Efficient Regioselective and Chemoselective Synthesis of New Substituted 3‐Methyl‐6‐arylpyridazine‐4‐carboxamides and 5‐Oxo‐3‐aryl‐5, 6‐dihydropyrido [4, 3‐c] pyridazine‐8‐carbaldehydes | |
JP2018087173A (ja) | 悪性脳腫瘍治療薬 |